Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 207Neoplasms 130Polycystic Ovary Syndrome 107Carcinoma, Hepatocellular 82Colorectal Neoplasms 77Prostatic Neoplasms 70Stomach Neoplasms 55Lung Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Carcinoma, Non-Small-Cell Lung 43Pancreatic Neoplasms 41Pain, Postoperative 41Head and Neck Neoplasms 38Pain 37Liver Neoplasms 36Leukemia, Myeloid, Acute 32Leiomyoma 32Keratosis, Actinic 31Colonic Neoplasms 31Recurrence 30Neoplasm Metastasis 29Multiple Myeloma 28Infertility 28Brain Neoplasms 28Uterine Cervical Neoplasms 26Urinary Bladder Neoplasms 24Ovarian Neoplasms 24Lymphoma 24Esophageal Neoplasms 23Obesity 22

Interventions

rasburicase 1Uric Acid 1Urate Oxidase 1Pegloticase 1Oxidoreductases 1Carbamates 1Amides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × OTHER × Tumor Lysis Syndrome × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡